← Back to Search

Immunotherapy

Bovine Colostrum for Gluten Intolerance

Phase < 1
Recruiting
Led By Jocelyn Silvester, MD PhD
Research Sponsored by Milky Way Life Sciences LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours

Summary

This trial investigates whether hyperimmune bovine colostrum can help people on a strict gluten-free diet by reducing the amount of gluten their bodies absorb. The colostrum works like a sponge, soaking up gluten to prevent it from causing problems.

Who is the study for?
This trial is for healthy volunteers who have been strictly gluten-free for at least 3 months, whether due to celiac disease, non-celiac gluten sensitivity, or personal choice. Participants must not have active gastrointestinal diseases, severe reactions to gluten or milk proteins, recent use of digestive enzymes, certain medical conditions or medications as judged by the investigators, and cannot be pregnant.
What is being tested?
The study tests if bovine colostrum can prevent the absorption of gluten in people on a strict gluten-free diet. It's a double-blind cross-over trial where participants will unknowingly receive either bovine colostrum or a placebo while being challenged with oral gluten.
What are the potential side effects?
Potential side effects are not specified but may include reactions related to lactose intolerance given that bovine colostrum is derived from cow's milk. Also possible are allergic responses in individuals sensitive to beef or other components.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Gluten immunogenic peptides in urine
Secondary study objectives
Symptom score

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Bovine colostrumExperimental Treatment1 Intervention
Participant will receive 18g of bovine colostrum with apple sauce and 1g of gluten.
Group II: PlaceboPlacebo Group1 Intervention
Participant will receive 18g of placebo with apple sauce and 1g of gluten.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bovine colostrum
2014
Completed Phase 2
~200

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The primary treatment for Celiac Disease is a strict gluten-free diet, which prevents the immune response triggered by gluten, allowing the intestines to heal. Hyperimmune bovine colostrum is being studied for its potential to reduce gluten absorption, which could help limit the immune response and intestinal damage by reducing the amount of gluten that reaches the small intestine. These mechanisms are crucial for Celiac Disease patients as they emphasize the importance of dietary management and the potential for new therapies to offer additional protection against gluten exposure.

Find a Location

Who is running the clinical trial?

Milky Way Life Sciences LLCLead Sponsor
Beth Israel Deaconess Medical CenterOTHER
853 Previous Clinical Trials
12,929,939 Total Patients Enrolled
5 Trials studying Celiac Disease
100 Patients Enrolled for Celiac Disease
Jocelyn Silvester, MD PhDPrincipal InvestigatorBeth Israel Deaconess Medical Center

Media Library

Bovine colostrum (Immunotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT05555446 — Phase < 1
Celiac Disease Research Study Groups: Bovine colostrum, Placebo
Celiac Disease Clinical Trial 2023: Bovine colostrum Highlights & Side Effects. Trial Name: NCT05555446 — Phase < 1
Bovine colostrum (Immunotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05555446 — Phase < 1
Celiac Disease Patient Testimony for trial: Trial Name: NCT05555446 — Phase < 1
~3 spots leftby Nov 2025